Southeast Chapter of the SCCM Bi-monthly Meeting – February 4, 2016



  • Explain the scientific rationale supporting the investigation and the approval process for antidotes specific to NOAC.
  • Compare the inclusion and exclusion criteria for the ongoing RE-VERSE-AD and ANNEXA-4 clinical trials.
  • Present clinical scenarios where NOAC antidotes could be considered for a patient.